Peroxisome proliferator-activated receptors in macrophage biology: Friend or foe?

Current Opinion in Lipidology

Volumn 12, Issue 5, 2001, Pages 519-527

  Moore, K J ^a   Fitzgerald, M L ^a   Freeman, M W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; AD 5075; CIGLITAZONE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHORBOL 13 ACETATE 12 MYRISTATE; ROSIGLITAZONE; STAT PROTEIN; TRANSCRIPTION FACTOR AP 1; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CYTOKINE PRODUCTION; HUMAN; IMMUNOREGULATION; INFLAMMATION; LIGAND BINDING; LIPID METABOLISM; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ARTERIOSCLEROSIS; CELL DIFFERENTIATION; HUMANS; INFLAMMATION; LIPID METABOLISM; MACROPHAGES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0034774075     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200110000-00007     Document Type: Review

References (46)

1. Roles of PPARs in health and disease
2. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
3. PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL
4. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARg
5. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
6. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake
7. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
8. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
9. Expression of the peroxisome proliferator-activated receptor g (PPARg) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoproteins
10. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo
11. Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells
12. 12,14-prostaglandin J2 inhibits the beta2 integrin-dependent oxidative burst: Involvement of a mechanism distinct from peroxisome proliferator-activated receptor gamma ligation
13. Cyclopentenone prostaglandins-new allies in the war on inflammation
14. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway
15. Anti-inflammatory cyclopentanone prostaglandins are direct inhibitors of IkappaB kinase
16. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
17. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
18. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways
19. Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation
20. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene
21. Nuclear receptor coregulators: Cellular and molecular biology
22. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
23. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
24. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma
25. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
26. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
27. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro
28. Atherosclerosis- an inflammatory disease
29. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists
30. PPARgamma in monocytes: Less pain, any gain?
31. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
32. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
33. Cholesterol efflux regulatory protein. Tangier disease and familial high-density lipoprotein deficiency
34. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha
35. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
36. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
37. Inhibition of oxidation of low density lipoprotein by troglitazone
38. Another potential use of troglitazone in noninsulin-dependent diabetes mellitus
39. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
40. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats
41. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
42. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL
43. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
44. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies
45. Peroxisome proliferator-activated receptor (PPAR) gamma: A new target for the treatment of inflammatory bowel disease
46. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response